Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale
Seres Therapeutics (MCRB) has received a $50 million installment payment from Nestlé Health Science, related to the previously announced sale of its VOWST business. This payment was received as planned, with Seres meeting its transition obligations. The company anticipates an additional $25 million installment payment (less approximately $1.5M in employment-related payments) from Nestlé Health Science in July 2025. Based on current cash position, including these payments and considering transaction-related obligations and operating plans, Seres expects to maintain operational funding into the first quarter of 2026.
Seres Therapeutics (MCRB) ha ricevuto un pagamento rateale di 50 milioni di dollari da Nestlé Health Science, relativo alla vendita precedentemente annunciata della sua attività VOWST. Questo pagamento è stato ricevuto come previsto, con Seres che ha soddisfatto i propri obblighi di transizione. L'azienda prevede un ulteriore pagamento rateale di 25 milioni di dollari (meno circa 1,5 milioni di dollari per pagamenti legati all'occupazione) da Nestlé Health Science nel luglio 2025. Sulla base della posizione di liquidità attuale, includendo questi pagamenti e considerando gli obblighi legati alla transazione e i piani operativi, Seres si aspetta di mantenere un finanziamento operativo fino al primo trimestre del 2026.
Seres Therapeutics (MCRB) ha recibido un pago a plazos de 50 millones de dólares de Nestlé Health Science, relacionado con la venta previamente anunciada de su negocio VOWST. Este pago fue recibido según lo planeado, con Seres cumpliendo sus obligaciones de transición. La compañía anticipa un pago adicional a plazos de 25 millones de dólares (menos aproximadamente 1.5 millones de dólares en pagos relacionados con el empleo) de Nestlé Health Science en julio de 2025. Con base en la posición de efectivo actual, incluyendo estos pagos y considerando las obligaciones relacionadas con la transacción y los planes operativos, Seres espera mantener un financiamiento operativo hasta el primer trimestre de 2026.
세레스 테라퓨틱스 (MCRB)는 네슬레 헬스 사이언스(Nestlé Health Science)로부터 자사의 VOWST 사업 매각과 관련된 5천만 달러의 분할 지급금을 받았습니다. 이 지급금은 계획대로 수령되었으며, 세레스는 전환 의무를 충족했습니다. 이 회사는 2025년 7월에 네슬레 헬스 사이언스로부터 추가로 2천5백만 달러의 분할 지급금 (약 150만 달러의 고용 관련 지급을 제외하고)을 예상하고 있습니다. 현재 자금 상황을 고려할 때, 이러한 지급금과 거래 관련 의무 및 운영 계획을 포함하여 세레스는 2026년 1분기까지 운영 자금을 유지할 것으로 기대하고 있습니다.
Seres Therapeutics (MCRB) a reçu un paiement échelonné de 50 millions de dollars de Nestlé Health Science, lié à la vente précédemment annoncée de son activité VOWST. Ce paiement a été reçu comme prévu, Seres ayant rempli ses obligations de transition. La société prévoit un paiement échelonné supplémentaire de 25 millions de dollars (moins environ 1,5 million de dollars en paiements liés à l'emploi) de Nestlé Health Science en juillet 2025. Sur la base de la situation de trésorerie actuelle, en tenant compte de ces paiements et des obligations liées à la transaction ainsi que des plans d'exploitation, Seres s'attend à maintenir un financement opérationnel jusqu'au premier trimestre 2026.
Seres Therapeutics (MCRB) hat eine Ratenzahlung von 50 Millionen Dollar von Nestlé Health Science erhalten, die mit dem zuvor angekündigten Verkauf ihres VOWST-Geschäfts zusammenhängt. Diese Zahlung wurde planmäßig erhalten, wobei Seres seine Übergangspflichten erfüllt hat. Das Unternehmen erwartet eine zusätzliche Ratenzahlung von 25 Millionen Dollar (abzüglich etwa 1,5 Millionen Dollar an arbeitsbezogenen Zahlungen) von Nestlé Health Science im Juli 2025. Basierend auf der aktuellen Liquidität, einschließlich dieser Zahlungen und in Anbetracht der transaktionsbezogenen Verpflichtungen und Betriebspläne, geht Seres davon aus, dass es die operationale Finanzierung bis ins erste Quartal 2026 aufrechterhalten kann.
- Receipt of significant $50M installment payment strengthening cash position
- Additional $25M payment expected in July 2025
- Cash runway extended into Q1 2026
- Future installment payment subject to $1.5M reduction for employment-related payments
Insights
The receipt of
The structured payment approach from the VOWST business sale to Nestlé Health Science demonstrates effective deal execution and milestone achievement. For a company of this size, these payments are materially significant and help mitigate cash burn concerns. The successful fulfillment of transition obligations suggests smooth operational handover and potential for maintaining positive relationship with Nestlé Health Science for future collaborations.
In simpler terms: Think of this like receiving a large scheduled payment on a house you've sold, where you agreed to help the new owners settle in. The money helps ensure you can keep your business running smoothly for another year without needing to ask for loans or sell more shares.
The successful transition of VOWST, a microbiome therapeutic for recurrent C. difficile infection, showcases Seres' ability to develop and monetize breakthrough treatments. This payment validates their business model of developing innovative live biotherapeutics and partnering with larger pharmaceutical companies for commercialization. The extended cash runway allows continued investment in their pipeline, particularly important for advancing other microbiome-based therapeutics.
The transaction with Nestlé Health Science, a major player in nutritional science and healthcare, adds credibility to Seres' technology platform. Meeting transition milestones on schedule indicates strong operational execution and potentially positions them favorably for future partnerships. This is especially important given the emerging nature of the microbiome therapeutics field.
For the average person: Imagine you've created a revolutionary new medicine and sold it to a big company. They're paying you in installments while you help them learn how to make and sell it. This payment shows you're doing a good job teaching them and you'll have enough money to work on your next breakthrough medicine.
CAMBRIDGE, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, announced today the receipt of a
As previously announced, based on the Company’s existing cash, inclusive of this payment, a projected installment payment from Nestlé Health Science in July 2025 of
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. Seres led the successful development and approval of VOWST™, the first FDA-approved orally administered microbiome therapeutic, which was sold to Nestlé Health Science in September 2024. The Company is developing SER-155, which has received both Breakthrough Therapy and Fast Track designation, and which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT. SER-155 and the Company's other pipeline programs are designed to target multiple disease-relevant pathways and are manufactured from standard clonal cell banks via cultivation, rather than from the donor-sourced production process used for VOWST. In addition to allo-HSCT, the Company intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically vulnerable patient populations including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities. For more information, please visit www.serestherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements about our anticipated financial performance, the receipt of an additional installment payment, projected cash runway, and other statements which are not historical fact.
These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: (1) we have incurred significant losses, are not currently profitable and may never become profitable; (2) our need for additional funding; (3) our history of operating losses; (4) our novel approach to therapeutic intervention; (5) our reliance on third parties to conduct our clinical trials and manufacture our product candidates; (6) the competition we will face; (7) our ability to protect our intellectual property; (8) our ability to retain key personnel and to manage our growth; (9) the effect of the VOWST sale on our ability to retain and hire key personnel and maintain relationships with our customers, suppliers, advertisers, partners and others with whom we do business, or on our operating results and businesses generally; (10) the risks associated with the disruption of management’s attention from ongoing business operations due to the obligation to provide transition services; (11) our failure to receive the installment payments or the milestone payments in the future; (12) the uncertainty of impact of the 50/50 profit and loss sharing arrangement on our reported results and liquidity; and (13) we may not be able to realize the anticipated benefits of the VOWST sale. These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC), on November 13, 2024, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Investor and Media Contacts:
IR@serestherapeutics.com
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
FAQ
How much was the installment payment received by Seres Therapeutics (MCRB) for the VOWST sale?
When will MCRB receive the next installment payment from Nestlé Health Science?
How long will MCRB's current cash runway last?
What is the total value of expected payments from the VOWST sale for MCRB in 2025?
